Company facts
- Headquarters
- San Diego, California
- Most recent report
- 8-K/A, filed Nov 9, 2026
- Incorporated
- Delaware
- Filings on record
- 234 filings
- On EDGAR
- CIK 1817241
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 8 of 11
News 8 of 23
Prospectuses and Registrations 8 of 16
- S-8 Registration statement for an employee plan Sep 11, 2026
- S-3 Shelf registration statement Aug 6, 2026
- 424B5 Prospectus supplement for an offering May 8, 2026
- FWP Free writing prospectus May 8, 2026
- S-8 Registration statement for an employee plan Mar 10, 2026
- S-3 Shelf registration statement Aug 6, 2025
- S-8 Registration statement for an employee plan Aug 6, 2025
- S-8 Registration statement for an employee plan Jul 22, 2024
Proxies 3
Ownership 8 of 156
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Oct 7, 2026
- 144 Notice of a proposed sale of restricted stock Oct 6, 2026
- 4 Insider reported a trade Oct 6, 2026
- 4 Insider reported a trade Oct 6, 2026
Other 8 of 25
- EFFECT Notice that a registration became effective Aug 14, 2026
- ARS Annual report sent to shareholders Aug 3, 2026
- EFFECT Notice that a registration became effective Aug 15, 2025
- CORRESP Reply to SEC staff Aug 13, 2025
- UPLOAD Comment letter from SEC staff Aug 11, 2025
- ARS Annual report sent to shareholders Apr 29, 2025
- SEC STAFF LETTER Jul 19, 2024
- EFFECT Notice that a registration became effective Jul 18, 2024
Everything here comes from Artiva Biotherapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.